All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or Myeloma crowd.
On March 24, 2022, it was announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) provide a positive opinion for granting a conditional marketing authorization for the use of ciltacabtagene autoleucel (cilta-cel) for the treatment of adult patients with relapsed/refractory multiple myeloma (RRMM). The marketing authorization is for patients who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody, and have demonstrated disease progression on the last therapy.1
Cilta-cel is a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell therapy, which has recently been granted approval by the U.S. Food and Drug Administration (FDA) in this patient population based on results of the CARTITUDE-1 trial. Read more about this here.
The impact of CAR T-cell therapy on quality of life of patients with triple-class refractory multiple myeloma
Over the last 15 years, novel treatments have significantly improved the overall survival of patients with multiple myeloma (MM). As...
Initial results of cilta-cel, a CAR T-cell therapy, in earlier lines of treatment
During the 2021 ASCO Annual Meeting and the EHA2021 Virtual Congress, the Multiple Myeloma Hub spoke with Mounzer Agha, UPMC Hillman Cancer Center, Pittsburgh, US. We...
Subscribe to get the best content related to multiple myeloma delivered to your inbox